DIANTHUS THERAPEUTICS INC (DNTH)
US2528281080 - Common Stock
Dianthus Therapeutics to Participate in Three Healthcare Investor Conferences in September
Commit To Buy Dianthus Therapeutics At $25, Earn 26.1% Annualized Using Options
DNTH Stock Earnings: Dianthus Therapeutics Beats EPS, Beats Revenue for Q2 2024
DNTH stock results show that Dianthus Therapeutics beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.
DNTH Stock Earnings: Dianthus Therapeutics Beats EPS, Beats Revenue for Q2 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Dianthus Therapeutics (NASDAQ:DNTH) just reported results for the second quarte...
Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q2 Financial Results
Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q2 Financial Results
Phase 2 MaGic trial in generalized Myasthenia Gravis (gMG) ongoing; top-line results anticipated in 2H’25 IND for Phase 2 MoMeNtum trial in Multifocal...
Dianthus Therapeutics Announces Two Poster Presentations for DNTH103 at the 10th Congress of the European Academy of Neurology (EAN)
Dianthus Therapeutics Announces Two Poster Presentations for DNTH103 at the 10th Congress of the European Academy of Neurology (EAN)
NEW YORK and WALTHAM, Mass., June 28, 2024 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company...
Dianthus Therapeutics Announces FDA Clearance to Initiate Phase 2 Trial of DNTH103 in Multifocal Motor Neuropathy (MMN)
Dianthus Therapeutics Announces FDA Clearance to Initiate Phase 2 Trial of DNTH103 in Multifocal Motor Neuropathy (MMN)
Top-line results from Phase 2 MoMeNtum trial in Multifocal Motor Neuropathy anticipated in 2H 2026 Building a neuromuscular franchise with DNTH103...
Dianthus Therapeutics to Participate in the Jefferies Global Healthcare Conference
Dianthus Therapeutics to Participate in the Jefferies Global Healthcare Conference
NEW YORK and WALTHAM, Mass., May 30, 2024 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company...
DNTH Stock Earnings: Dianthus Therapeutics Misses EPS, Beats Revenue for Q1 2024
DNTH stock results show that Dianthus Therapeutics missed analyst estimates for earnings per share but beat on revenue for the first quarter of 2024.
DNTH Stock Earnings: Dianthus Therapeutics Misses EPS, Beats Revenue for Q1 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Dianthus Therapeutics (NASDAQ:DNTH) just reported results for the first quarter...
Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q1 Financial Results
Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q1 Financial Results
Phase 2 MaGic trial in generalized Myasthenia Gravis (gMG) ongoing, with top-line results anticipated in 2H’25 Building a neuromuscular franchise with...
Dianthus Therapeutics to Participate in the Bank of America Securities 2024 Health Care Conference
Dianthus Therapeutics to Participate in the Bank of America Securities 2024 Health Care Conference
NEW YORK and WALTHAM, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company...
Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEW YORK and WALTHAM, Mass., May 03, 2024 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (“Dianthus”), a clinical-stage biotechnology company dedicated...
Dianthus Therapeutics Announces Oral Presentation for DNTH103 at the 2024 American Academy of Neurology (AAN) Annual Meeting
Dianthus Therapeutics Announces Oral Presentation for DNTH103 at the 2024 American Academy of Neurology (AAN) Annual Meeting
NEW YORK and WALTHAM, Mass., April 11, 2024 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company...
Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEW YORK and WALTHAM, Mass., April 05, 2024 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (“Dianthus”), a clinical-stage biotechnology company...
DNTH Stock Earnings: Dianthus Therapeutics Beats EPS, Beats Revenue for Q4 2023
DNTH stock results show that Dianthus Therapeutics beat analyst estimates for earnings per share and beat on revenue for the fourth quarter of 2023.
DNTH Stock Earnings: Dianthus Therapeutics Beats EPS, Beats Revenue for Q4 2023
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Dianthus Therapeutics (NASDAQ:DNTH) just reported results for the fourth quarte...
Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q4 and FY2023 Financial Results
Phase 2 MaGic trial in generalized Myasthenia Gravis (gMG) initiated in Q1’24 with top-line results anticipated in 2H’25 $389 million of pro forma cash,...
Dianthus Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Dianthus Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
NEW YORK and and WALTHAM, Mass., March 07, 2024 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH) (“Dianthus”), a clinical-stage...
Dianthus Therapeutics Announces Initiation of Phase 2 MaGic Trial of DNTH103 In Generalized Myasthenia Gravis (gMG)
Dianthus Therapeutics Announces Initiation of Phase 2 MaGic Trial of DNTH103 In Generalized Myasthenia Gravis (gMG)
Top-line results from gMG MaGic trial anticipated in 2H 2025
Stifel starts Dianthus at buy, cites market potential of lead drug (NASDAQ:DNTH)
Stifel started coverage of Dianthus Therapeutics (DNTH) with a buy rating, citing the market potential of its lead drug candidate DNTH103. Read more here.